併用化学療法、ベバシズマブ、および/またはアテゾリズマブによる DNA ミスマッチ修復欠損患者の治療、転移性結腸直腸癌、COMMIT 研究
結腸直腸癌転移性 dMMR/MSI-H 免疫療法 (COMMIT) 研究: DNA ミスマッチ修復 (dMMR)/マイクロサテライト欠損患者の一次治療における mFOLFOX6/ベバシズマブ/アテゾリズマブ併用療法とアテゾリズマブ単剤療法の無作為化第 III 相研究不安定性の高い(MSI-H)転移性結腸直腸がん
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Kingman、Arizona、アメリカ、86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim、California、アメリカ、92806
- Kaiser Permanente-Anaheim
-
Baldwin Park、California、アメリカ、91706
- Kaiser Permanente-Baldwin Park
-
Bellflower、California、アメリカ、90706
- Kaiser Permanente-Bellflower
-
Berkeley、California、アメリカ、94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord、California、アメリカ、94520
- John Muir Medical Center-Concord
-
Fontana、California、アメリカ、92335
- Kaiser Permanente-Fontana
-
Harbor City、California、アメリカ、90710
- Kaiser Permanente South Bay
-
Irvine、California、アメリカ、92618
- Kaiser Permanente-Irvine
-
Los Angeles、California、アメリカ、90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles、California、アメリカ、90034
- Kaiser Permanente West Los Angeles
-
Marysville、California、アメリカ、95901
- Fremont - Rideout Cancer Center
-
Modesto、California、アメリカ、95355
- Memorial Medical Center
-
Ontario、California、アメリカ、91761
- Kaiser Permanente-Ontario
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange、California、アメリカ、92868
- Saint Joseph Hospital - Orange
-
Panorama City、California、アメリカ、91402
- Kaiser Permanente - Panorama City
-
Riverside、California、アメリカ、92505
- Kaiser Permanente-Riverside
-
Sacramento、California、アメリカ、95816
- Sutter Medical Center Sacramento
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
Salinas、California、アメリカ、93901
- Salinas Valley Memorial
-
San Diego、California、アメリカ、92120
- Kaiser Permanente-San Diego Zion
-
San Diego、California、アメリカ、92108
- Kaiser Permanente-Rio San Diego
-
San Marcos、California、アメリカ、92078
- Kaiser Permanente-San Marcos
-
Walnut Creek、California、アメリカ、94598
- John Muir Medical Center-Walnut Creek
-
Whittier、California、アメリカ、90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills、California、アメリカ、91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
Boulder、Colorado、アメリカ、80303
- Boulder Community Foothills Hospital
-
Boulder、Colorado、アメリカ、80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs、Colorado、アメリカ、80909
- UCHealth Memorial Hospital Central
-
Colorado Springs、Colorado、アメリカ、80920
- Memorial Hospital North
-
Denver、Colorado、アメリカ、80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver、Colorado、アメリカ、80220
- Rocky Mountain Cancer Centers-Rose
-
Denver、Colorado、アメリカ、80204
- Denver Health Medical Center
-
Denver、Colorado、アメリカ、80206
- National Jewish Health-Main Campus
-
Denver、Colorado、アメリカ、80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Englewood、Colorado、アメリカ、80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood、Colorado、アメリカ、80113
- Swedish Medical Center
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- Cancer Care and Hematology-Fort Collins
-
Golden、Colorado、アメリカ、80401
- National Jewish Health-Western Hematology Oncology
-
Greeley、Colorado、アメリカ、80631
- UCHealth Greeley Hospital
-
Greeley、Colorado、アメリカ、80631
- Banner North Colorado Medical Center
-
Littleton、Colorado、アメリカ、80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree、Colorado、アメリカ、80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland、Colorado、アメリカ、80538
- Medical Center of the Rockies
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton、Colorado、アメリカ、80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge、Colorado、アメリカ、80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury、Connecticut、アメリカ、06810
- Danbury Hospital
-
Hartford、Connecticut、アメリカ、06102
- Hartford Hospital
-
Meriden、Connecticut、アメリカ、06451
- Midstate Medical Center
-
New Britain、Connecticut、アメリカ、06050
- The Hospital of Central Connecticut
-
Norwich、Connecticut、アメリカ、06360
- William Backus Hospital
-
-
Delaware
-
Millville、Delaware、アメリカ、19967
- Beebe South Coastal Health Campus
-
Newark、Delaware、アメリカ、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、アメリカ、19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach、Delaware、アメリカ、19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33316
- Broward Health Medical Center
-
Fort Myers、Florida、アメリカ、33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville、Florida、アメリカ、32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville、Florida、アメリカ、32207
- Baptist MD Anderson Cancer Center
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Albany、Georgia、アメリカ、31701
- Phoebe Putney Memorial Hospital
-
Athens、Georgia、アメリカ、30607
- University Cancer and Blood Center LLC
-
Augusta、Georgia、アメリカ、30912
- Augusta University Medical Center
-
Augusta、Georgia、アメリカ、30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta、Georgia、アメリカ、30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan、Georgia、アメリカ、30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、アメリカ、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、アメリカ、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、アメリカ、61021
- Illinois CancerCare-Dixon
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Evanston、Illinois、アメリカ、60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Glenview、Illinois、アメリカ、60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park、Illinois、アメリカ、60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood、Illinois、アメリカ、60153
- Loyola University Medical Center
-
Mount Vernon、Illinois、アメリカ、62864
- SSM Health Good Samaritan
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Washington、Illinois、アメリカ、61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46237
- Franciscan Health Indianapolis
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis、Indiana、アメリカ、46219
- Community Cancer Center East
-
Indianapolis、Indiana、アメリカ、46227
- Community Cancer Center South
-
Indianapolis、Indiana、アメリカ、46256
- Community Cancer Center North
-
Kokomo、Indiana、アメリカ、46904
- Community Howard Regional Health
-
Lafayette、Indiana、アメリカ、47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City、Indiana、アメリカ、46360
- Woodland Cancer Care Center
-
Mooresville、Indiana、アメリカ、46158
- Franciscan Health Mooresville
-
Terre Haute、Indiana、アメリカ、47804
- Union Hospital
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- Mary Greeley Medical Center
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Bettendorf、Iowa、アメリカ、52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone、Iowa、アメリカ、50036
- McFarland Clinic - Boone
-
Cedar Rapids、Iowa、アメリカ、52403
- Mercy Hospital
-
Cedar Rapids、Iowa、アメリカ、52403
- Oncology Associates at Mercy Medical Center
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50314
- Broadlawns Medical Center
-
Des Moines、Iowa、アメリカ、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge、Iowa、アメリカ、50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge、Iowa、アメリカ、50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson、Iowa、アメリカ、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、アメリカ、50158
- McFarland Clinic - Marshalltown
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays、Kansas、アメリカ、67601
- HaysMed
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Olathe、Kansas、アメリカ、66061
- The University of Kansas Cancer Center - Olathe
-
Salina、Kansas、アメリカ、67401
- Salina Regional Health Center
-
Topeka、Kansas、アメリカ、66606
- University of Kansas Health System Saint Francis Campus
-
Westwood、Kansas、アメリカ、66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
Lexington、Kentucky、アメリカ、40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville、Kentucky、アメリカ、40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville、Kentucky、アメリカ、40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville、Kentucky、アメリカ、40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner、Louisiana、アメリカ、70065
- Ochsner Medical Center Kenner
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta、Maine、アメリカ、04330
- Harold Alfond Center for Cancer Care
-
Bangor、Maine、アメリカ、04401
- Eastern Maine Medical Center
-
Belfast、Maine、アメリカ、04915
- MaineHealth Waldo Hospital
-
Biddeford、Maine、アメリカ、04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer、Maine、アメリカ、04412
- Lafayette Family Cancer Center-EMMC
-
Rockport、Maine、アメリカ、04856
- Penobscot Bay Medical Center
-
Sanford、Maine、アメリカ、04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland、Maine、アメリカ、04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton、Maryland、アメリカ、21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg、Maryland、アメリカ、20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo、Maryland、アメリカ、20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville、Maryland、アメリカ、21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Lowell、Massachusetts、アメリカ、01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City、Michigan、アメリカ、48706
- McLaren Cancer Institute-Bay City
-
Bloomfield、Michigan、アメリカ、48302
- McLaren Cancer Institute-Bloomfield
-
Brighton、Michigan、アメリカ、48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton、Michigan、アメリカ、48114
- Trinity Health Medical Center - Brighton
-
Brownstown、Michigan、アメリカ、48183
- Henry Ford Cancer Institute-Downriver
-
Canton、Michigan、アメリカ、48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton、Michigan、アメリカ、48188
- Trinity Health Medical Center - Canton
-
Chelsea、Michigan、アメリカ、48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea、Michigan、アメリカ、48118
- Chelsea Hospital
-
Clarkston、Michigan、アメリカ、48346
- McLaren Cancer Institute-Clarkston
-
Clarkston、Michigan、アメリカ、48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston、Michigan、アメリカ、48346
- Newland Medical Associates-Clarkston
-
Clinton Township、Michigan、アメリカ、48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn、Michigan、アメリカ、48126
- Henry Ford Medical Center-Fairlane
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
Detroit、Michigan、アメリカ、48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills、Michigan、アメリカ、48334
- Weisberg Cancer Treatment Center
-
Flint、Michigan、アメリカ、48532
- McLaren Cancer Institute-Flint
-
Flint、Michigan、アメリカ、48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids、Michigan、アメリカ、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson、Michigan、アメリカ、49201
- Allegiance Health
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Lansing、Michigan、アメリカ、48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer、Michigan、アメリカ、48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia、Michigan、アメリカ、48154
- Hope Cancer Clinic
-
Mount Clemens、Michigan、アメリカ、48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant、Michigan、アメリカ、48858
- McLaren Cancer Institute-Central Michigan
-
Novi、Michigan、アメリカ、48377
- Henry Ford Medical Center-Columbus
-
Petoskey、Michigan、アメリカ、49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron、Michigan、アメリカ、48060
- McLaren-Port Huron
-
Saginaw、Michigan、アメリカ、48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw、Michigan、アメリカ、48601
- MyMichigan Medical Center Saginaw
-
Tawas City、Michigan、アメリカ、48764
- MyMichigan Medical Center Tawas
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
West Bloomfield、Michigan、アメリカ、48322
- Henry Ford West Bloomfield Hospital
-
West Branch、Michigan、アメリカ、48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti、Michigan、アメリカ、48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji、Minnesota、アメリカ、56601
- Sanford Joe Lueken Cancer Center
-
Burnsville、Minnesota、アメリカ、55337
- Minnesota Oncology - Burnsville
-
Deer River、Minnesota、アメリカ、56636
- Essentia Health - Deer River Clinic
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Hibbing、Minnesota、アメリカ、55746
- Essentia Health Hibbing Clinic
-
Maplewood、Minnesota、アメリカ、55109
- Saint John's Hospital - Healtheast
-
Maplewood、Minnesota、アメリカ、55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis、Minnesota、アメリカ、55415
- Hennepin County Medical Center
-
Minneapolis、Minnesota、アメリカ、55454
- Health Partners Inc
-
Saint Paul、Minnesota、アメリカ、55101
- Regions Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- United Hospital
-
Sandstone、Minnesota、アメリカ、55072
- Essentia Health Sandstone
-
Virginia、Minnesota、アメリカ、55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada、Mississippi、アメリカ、38901
- Baptist Cancer Center-Grenada
-
New Albany、Mississippi、アメリカ、38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford、Mississippi、アメリカ、38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven、Mississippi、アメリカ、38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin、Missouri、アメリカ、63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
Columbia、Missouri、アメリカ、65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin、Missouri、アメリカ、64804
- Freeman Health System
-
Joplin、Missouri、アメリカ、64804
- Mercy Hospital Joplin
-
Kansas City、Missouri、アメリカ、64108
- University Health Truman Medical Center
-
St Louis、Missouri、アメリカ、63109
- Mercy Infusion Center - Chippewa
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Helena、Montana、アメリカ、59601
- Saint Peter's Community Hospital
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59804
- Community Medical Center
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89102
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、アメリカ、89128
- OptumCare Cancer Care at MountainView
-
Las Vegas、Nevada、アメリカ、89183
- OptumCare Cancer Care at Fort Apache
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester、New Hampshire、アメリカ、03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua、New Hampshire、アメリカ、03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton、New Jersey、アメリカ、08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
Paramus、New Jersey、アメリカ、07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood、New Jersey、アメリカ、07450
- Valley Health System Ridgewood Campus
-
Somerville、New Jersey、アメリカ、08876
- Robert Wood Johnson University Hospital Somerset
-
Summit、New Jersey、アメリカ、07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
Albuquerque、New Mexico、アメリカ、87110
- Presbyterian Kaseman Hospital
-
Las Cruces、New Mexico、アメリカ、88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho、New Mexico、アメリカ、87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Elmira、New York、アメリカ、14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success、New York、アメリカ、11042
- Northwell Health/Center for Advanced Medicine
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester、New York、アメリカ、14642
- University of Rochester
-
White Plains、New York、アメリカ、10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville、North Carolina、アメリカ、28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville、North Carolina、アメリカ、28349
- ECU Health Oncology Kenansville
-
Kinston、North Carolina、アメリカ、28501
- ECU Health Oncology Kinston
-
Pinehurst、North Carolina、アメリカ、28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands、North Carolina、アメリカ、28574
- ECU Health Oncology Richlands
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Sanford Bismarck Medical Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- Sanford Broadway Medical Center
-
Grand Forks、North Dakota、アメリカ、58201
- Altru Cancer Center
-
-
Ohio
-
Akron、Ohio、アメリカ、44307
- Cleveland Clinic Akron General
-
Belpre、Ohio、アメリカ、45714
- Strecker Cancer Center-Belpre
-
Centerville、Ohio、アメリカ、45459
- Miami Valley Hospital South
-
Centerville、Ohio、アメリカ、45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe、Ohio、アメリカ、45601
- Adena Regional Medical Center
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Columbus、Ohio、アメリカ、43219
- The Mark H Zangmeister Center
-
Columbus、Ohio、アメリカ、43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus、Ohio、アメリカ、43228
- Doctors Hospital
-
Columbus、Ohio、アメリカ、43213
- Mount Carmel East Hospital
-
Columbus、Ohio、アメリカ、43215
- Grant Medical Center
-
Columbus、Ohio、アメリカ、43222
- Mount Carmel Health Center West
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Delaware、Ohio、アメリカ、43015
- Delaware Health Center-Grady Cancer Center
-
Delaware、Ohio、アメリカ、43015
- Grady Memorial Hospital
-
Kettering、Ohio、アメリカ、45409
- Greater Dayton Cancer Center
-
Lancaster、Ohio、アメリカ、43130
- Fairfield Medical Center
-
Mansfield、Ohio、アメリカ、44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield、Ohio、アメリカ、44903
- OhioHealth Mansfield Hospital
-
Marietta、Ohio、アメリカ、45750
- Marietta Memorial Hospital
-
Marion、Ohio、アメリカ、43302
- OhioHealth Marion General Hospital
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon、Ohio、アメリカ、43050
- Knox Community Hospital
-
Newark、Ohio、アメリカ、43055
- Licking Memorial Hospital
-
Portsmouth、Ohio、アメリカ、45662
- Southern Ohio Medical Center
-
Sandusky、Ohio、アメリカ、44870
- North Coast Cancer Care
-
Sylvania、Ohio、アメリカ、43560
- ProMedica Flower Hospital
-
Warrensville Heights、Ohio、アメリカ、44122
- South Pointe Hospital
-
West Chester、Ohio、アメリカ、45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville、Ohio、アメリカ、43081
- Saint Ann's Hospital
-
Zanesville、Ohio、アメリカ、43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton、Oklahoma、アメリカ、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa、Oklahoma、アメリカ、74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend、Oregon、アメリカ、97701
- Saint Charles Health System
-
Clackamas、Oregon、アメリカ、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、アメリカ、97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg、Oregon、アメリカ、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City、Oregon、アメリカ、97045
- Providence Willamette Falls Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown、Pennsylvania、アメリカ、18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem、Pennsylvania、アメリカ、18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem、Pennsylvania、アメリカ、18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton、Pennsylvania、アメリカ、18045
- Saint Luke's Hospital-Anderson Campus
-
Erie、Pennsylvania、アメリカ、16544
- Saint Vincent Hospital
-
Harrisburg、Pennsylvania、アメリカ、17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills、Pennsylvania、アメリカ、15025
- Jefferson Hospital
-
Monroeville、Pennsylvania、アメリカ、15146
- Forbes Hospital
-
Natrona Heights、Pennsylvania、アメリカ、15065
- Allegheny Valley Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15212
- Allegheny General Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15224
- West Penn Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
Quakertown、Pennsylvania、アメリカ、18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading、Pennsylvania、アメリカ、19611
- Reading Hospital
-
Wexford、Pennsylvania、アメリカ、15090
- Wexford Health and Wellness Pavilion
-
Willow Grove、Pennsylvania、アメリカ、19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson、South Carolina、アメリカ、29621
- AnMed Health Cancer Center
-
Beaufort、South Carolina、アメリカ、29902
- Beaufort Memorial Hospital
-
Boiling Springs、South Carolina、アメリカ、29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley、South Carolina、アメリカ、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Greer、South Carolina、アメリカ、29650
- Prisma Health Cancer Institute - Greer
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg、South Carolina、アメリカ、29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen、South Dakota、アメリカ、57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol、Tennessee、アメリカ、37620
- Bristol Regional Medical Center
-
Collierville、Tennessee、アメリカ、38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville、Tennessee、アメリカ、38501
- Cookeville Regional Medical Center
-
Johnson City、Tennessee、アメリカ、37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport、Tennessee、アメリカ、37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport、Tennessee、アメリカ、37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis、Tennessee、アメリカ、38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont、Texas、アメリカ、77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe、Texas、アメリカ、77384
- UT MD Anderson - The Woodlands
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg、Texas、アメリカ、78539
- STCC at DHR Health Institute for Research and Development
-
Houston、Texas、アメリカ、77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Houston、Texas、アメリカ、77079
- UT MD Anderson - West Houston
-
League City、Texas、アメリカ、77573
- UT MD Anderson - League City
-
Port Arthur、Texas、アメリカ、77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land、Texas、アメリカ、77478
- UT MD Anderson - Sugar Land
-
Temple、Texas、アメリカ、76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury、Vermont、アメリカ、05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol、Virginia、アメリカ、24201
- Ballad Health Cancer Care - Bristol
-
Burke、Virginia、アメリカ、22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville、Virginia、アメリカ、22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg、Virginia、アメリカ、24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean、Virginia、アメリカ、22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton、Virginia、アメリカ、24273
- Ballad Health Cancer Care - Norton
-
Richmond、Virginia、アメリカ、23235
- VCU Massey Cancer Center at Stony Point
-
Richmond、Virginia、アメリカ、23229
- Virginia Cancer Institute
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
South Hill、Virginia、アメリカ、23970
- VCU Community Memorial Health Center
-
Woodbridge、Virginia、アメリカ、22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend、Washington、アメリカ、98368
- Jefferson Healthcare
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Spokane、Washington、アメリカ、99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane、Washington、アメリカ、99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
Parkersburg、West Virginia、アメリカ、26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo、Wisconsin、アメリカ、54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton、Wisconsin、アメリカ、54911
- ThedaCare Regional Cancer Center
-
Appleton、Wisconsin、アメリカ、54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland、Wisconsin、アメリカ、54806
- Duluth Clinic Ashland
-
Brookfield、Wisconsin、アメリカ、53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin、Wisconsin、アメリカ、53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay、Wisconsin、アメリカ、54301
- Bellin Memorial Hospital
-
Janesville、Wisconsin、アメリカ、53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek、Wisconsin、アメリカ、53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison、Wisconsin、アメリカ、53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Medford、Wisconsin、アメリカ、54451
- Aspirus Medford Hospital
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Mukwonago、Wisconsin、アメリカ、53149
- ProHealth D N Greenwald Center
-
New Richmond、Wisconsin、アメリカ、54017
- Cancer Center of Western Wisconsin
-
Oconomowoc、Wisconsin、アメリカ、53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh、Wisconsin、アメリカ、54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine、Wisconsin、アメリカ、53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander、Wisconsin、アメリカ、54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha、Wisconsin、アメリカ、53188
- UW Cancer Center at ProHealth Care
-
Waukesha、Wisconsin、アメリカ、53188
- ProHealth Waukesha Memorial Hospital
-
Wausau、Wisconsin、アメリカ、54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa、Wisconsin、アメリカ、53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids、Wisconsin、アメリカ、54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne、Wyoming、アメリカ、82001
- Cheyenne Regional Medical Center-West
-
Cody、Wyoming、アメリカ、82414
- Billings Clinic-Cody
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo collection of blood samples
他の名前:
Given IV
他の名前:
Undergo CT or CT/PET
他の名前:
Given IV
他の名前:
Undergo CT/PET
他の名前:
|
|
実験的:Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo collection of blood samples
他の名前:
Given IV
他の名前:
Undergo CT or CT/PET
他の名前:
Undergo CT/PET
他の名前:
|
|
実験的:Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo collection of blood samples
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo CT or CT/PET
他の名前:
Given IV
他の名前:
Undergo CT/PET
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival (PFS)
時間枠:From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PFSの割合
時間枠:12ヶ月で
|
12ヶ月で
|
|
|
Overall survival (OS)
時間枠:The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
時間枠:Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
時間枠:Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
時間枠:At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
時間枠:From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
時間枠:From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Severity of fatigue
時間枠:At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
時間枠:At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
時間枠:Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
時間枠:Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
時間枠:Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
時間枠:Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
時間枠:Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
時間枠:Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
時間枠:Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
時間枠:Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
時間枠:Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
時間枠:Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
時間枠:Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
協力者と研究者
捜査官
- 主任研究者:Caio Max S Rocha Lima、NRG Oncology
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 腸の病気
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 腸の腫瘍
- 直腸疾患
- 結腸疾患
- 結腸直腸腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 酵素と補酵素
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 調整錯体
- ピリミジン
- 化学技術、分析
- スペクトル分析
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- ウラシル
- ピリミジノン
- コエンザイム
- 免疫グロブリンアイソタイプ
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- オキサリプラチン
- ベバシズマブ
- フルオロウラシル
- ロイコボリン
- 免疫グロブリンG
- 標本処理
- 磁気共鳴分光法
- ジスルフィド
- アテゾリズマブ
- Dehydroftorafur
その他の研究ID番号
- NCI-2016-01961
- U10CA180868 (米国 NIH グラント/契約)
- NCI-2016-01961 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (その他の識別子:CTEP)
- NRG-GI004 (その他の識別子:NRG Oncology)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。